公开(公告)号：US20240307536A1

公开(公告)日：2024-09-19

申请号：US18271883

申请日：2022-01-11

Applicant: Hadasit Medical Research Services and Development Ltd.

Inventor： Amnon PELED ,  Inbal MISHALIAN

IPC: A61K39/00 ,  A61P35/02 ,  C07K14/54 ,  C07K14/55 ,  C07K14/705 ,  C07K14/715 ,  C07K16/28 ,  C12N5/0783 ,  C12N9/64

CPC classification number: A61K39/4611 ,  A61K39/4631 ,  A61K39/4635 ,  A61K39/464402 ,  A61K39/464412 ,  A61P35/02 ,  C07K14/5443 ,  C07K14/55 ,  C07K14/7056 ,  C07K14/7158 ,  C07K16/2803 ,  C07K16/2866 ,  C12N5/0638 ,  C12N9/6467 ,  C12Y304/21079 ,  A61K2239/26 ,  A61K2239/48 ,  C07K2317/622 ,  C07K2317/73 ,  C12N2501/2302 ,  C12N2501/515 ,  C12N2510/00

Abstract: The present invention is directed to the field of immunotherapy. Specifically, the invention provides improved cell compositions and methods for adoptive cell therapy, useful in the treatment of cancer. More specifically, embodiments of the invention employ the use of cell compositions comprising a high proportion of activated cytotoxic CD8+ cells and in particular CD8+NKG2D+granzyme-B+ cells characterized by enhanced cytotoxicity, to processes for their preparation from peripheral blood mononuclear cells (PBMC), and to their use in cancer management.